JPRN-UMIN000001838已完成2 期
Phase II study of cetuximab plus irinotecan for unresectable colorectal cancer - Phase II study of cetuximab plus irinotecan for colorectal cancer
Aichi Cancer Center Hospital0 个研究点目标入组 30 人开始时间: 2009年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Symptomatic brain metastasis Wartery diarrhea Paralytic or mechanical bowel obstruction confirmed or suspected infection Severe pulmonary disease (interstitial pneumonia, pulmonary fobrosis, severe emphysematous) Severe comorbidity (uncontrolable diabetes, heart failure with NYHA 3 or 4, renal failure, liver failure) Sever neurologic disease history of irinotecan allergy past history of treatment with EGFR antibody
研究者
相似试验
进行中（未招募）
1 期
Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancerEUCTR2007-004232-22-DKOdense University Hospital
进行中（未招募）
1 期
Phase II trial with Cetuximab and Irinotecan (CetIri) for patients with platinum resistant esofagus- or gastric cancer - CetIriPatients with esofagus- and gastric cancerMedDRA version: 9.1Level: LLTClassification code 10017758Term: Gastric cancerEUCTR2008-006168-12-DKOdense University Hospital55
进行中（未招募）
不适用
Phase II study of therapy with Cetuximab and Irinotecan every second week to Irinotecan resistant patients with metastatic colorectal cancer-effect and biological markersIn Denmark there is approximately 3600 new cases of Colorectal cancer every year. In Denmark about half of these patients will eventually develop metastatic disease. In Denmark it is suggested that 150 patients each year will be in such good performance to third line chemotherapy.MedDRA version: 9Level: 1.0Classification code 10010029EUCTR2006-001961-40-DKDepartment of Oncology, University Hospital Herlev100
已完成
2 期
Phase II study of biweekly cetuximab+irinotecan therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011362Osaka City University20
已完成
2 期
Phase II study of biweekly cetuximab plus irinotecan for unresectable colorectal cancerJPRN-UMIN000001951Aichi Cancer Center Hospital30